BioSpace News Archive

Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that its partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma) has filed a New Drug Application (NDA) for the marketing authorization of isavuconazole (Cresemba ® ) in Japan for the treatment of the fungal infections aspergillosis, mucormycosis and cryptococcosis.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announce the participation of members of the company’s senior management in three investor and scientific conferences during October 2021.

Carbiodioxide (CO?) laser, argon laser, and Nd: YAG laser are various types of ENT surgery layers most widely used. CO? laser is a molecular gas laser containing CO2, nitrogen (N2), helium (He), hydrogen (H2), water vapor and/or xenon (Xe).

Fact.MR – A Market Research and Competitive Intelligence Provider: A study published by Fact.MR pegs the global dental cements market to total US$ 1.2 billion by 2025.

LEO Pharma A/S announced results showing adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity and sleep interference following two years of continuous treatment with tralokinumab.1 Interim findings from the Phase 3 ECZTEND trial were shared as an oral presentation during the European Academy of Dermatology and Venereology Congress 2021.

Aracari Biosciences, Inc. announces a Phase II Small Business Innovation Research award from the National Science Foundation to commercialize its proprietary Vasoreactive Vascularized Micro-Organ platform.

Trevena, Inc. today announced data from 30 patients enrolled in the proof-of-concept study of TRV027, the Company’s novel AT1 receptor selective agonist, in hospitalized COVID-19 patients.

Bausch + Lomb today announced statistically significant topline data from the second Phase 3 (MOJAVE) trial evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).

Leading U.S. surgeons and hospitals complete first commercial cases with NuVasive’s integrated enabling technology platform for spine surgery

CollPlant Biotechnologies has been invited to present at the Fall Harvest – Best Ideas from the Buy-Side conference, which is being held virtually on October 5th – 8th